After-market Movers For Feb 12 (CSCO, WFM, CBS, SKX, ANGI, ITRI, DRRX)

(RTTNews) - Gainers:

CBS Corp. (CBS) rose 4 percent to $64.54. The company's fourth quarter earnings were higher than in the year-ago quarter. Revenues grew 6 percent and noted that this growth was led by a 28 percent increase in content licensing and distribution revenues, which was driven by higher domestic and international licensing of television programming. CBS also announced plan to initiate an accelerated share repurchase of $1.5 billion of its Class B common stock during the first quarter of 2014.

Skechers USA Inc. (SKX) gained 13 percent to $34.04. The company's fourth quarter profit and revenues improved from the year-ago quarter and topped Street view.

Decliners:

Cisco Systems, Inc. (CSCO) was down 4 percent to $21.93. The company's second quarter earnings declined from the year-ago quarter, while its non-GAAP earnings per share topped Wall Street view. Total revenue decreased, but came above the consensus estimate. Cisco also raised its quarterly dividend by 12 percent.

Whole Foods Market, Inc. (WFM) declined 7 percent to $51.40. The company's first quarter earnings per share and revenue were below Wall Street view. The company lowered its fiscal year 2014 earnings per share outlook, below Street view. The company also lowered the top end of its sales growth ranges based on year-to-date trends.

Angie's List, Inc. (ANGI) fell 14 percent to $14.59. The company's fourth quarter earnings improved slightly from the year-ago quarter, but missed Wall Street view. Total revenue increased 49 percent and managed to come above the consensus estimate. The company forecast first quarter revenue below market view.

Itron, Inc. (ITRI) fell 13 percent to $34.00. The company slipped to a loss in its fourth quarter, while revenues missed the consensus estimate. The company guided full year 2014 results below Street view. The company also announced that its board authorized a new share repurchase program of up to $50 million of common stock.

DURECT Corp. (DRRX) plunged 30 percent to $1.38 based on the news that the FDA has issued a Complete Response Letter for POSIDUR (SABER-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form and has indicated that additional clinical safety studies need to be conducted.